IL6 and neoplasm: At these early timepoints after doxorubicin treatment, there is no significant difference in leukemic cell burden in the BM of IL-6 KO and WT mice (Fig. 3h), suggesting that the DNA damage induced by this agent may not account for its entire anti-tumor activity.